CL2020002793A1 - Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas. - Google Patents

Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas.

Info

Publication number
CL2020002793A1
CL2020002793A1 CL2020002793A CL2020002793A CL2020002793A1 CL 2020002793 A1 CL2020002793 A1 CL 2020002793A1 CL 2020002793 A CL2020002793 A CL 2020002793A CL 2020002793 A CL2020002793 A CL 2020002793A CL 2020002793 A1 CL2020002793 A1 CL 2020002793A1
Authority
CL
Chile
Prior art keywords
binding proteins
receptor binding
cannabinoid receptor
proteins type
type
Prior art date
Application number
CL2020002793A
Other languages
English (en)
Spanish (es)
Inventor
Antara Banerjee
Andrea Fanjul
Robert J Hoey
Kacey Sachen
Nikolai Suslov
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2020002793A1 publication Critical patent/CL2020002793A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2020002793A 2018-04-30 2020-10-27 Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas. CL2020002793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
CL2020002793A1 true CL2020002793A1 (es) 2021-02-12

Family

ID=67396963

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002793A CL2020002793A1 (es) 2018-04-30 2020-10-27 Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas.

Country Status (20)

Country Link
US (3) US12202901B2 (enExample)
EP (1) EP3787746A1 (enExample)
JP (2) JP7431750B2 (enExample)
KR (1) KR20210005051A (enExample)
CN (1) CN112218684A (enExample)
AR (1) AR114436A1 (enExample)
AU (1) AU2019264029A1 (enExample)
BR (1) BR112020022035A2 (enExample)
CA (1) CA3098416A1 (enExample)
CL (1) CL2020002793A1 (enExample)
CO (1) CO2020014681A2 (enExample)
EA (1) EA202092593A1 (enExample)
EC (1) ECSP20076576A (enExample)
MA (1) MA52504A (enExample)
MX (1) MX2020011498A (enExample)
PE (1) PE20210419A1 (enExample)
PH (1) PH12020551805A1 (enExample)
SG (1) SG11202010388SA (enExample)
TW (1) TWI882957B (enExample)
WO (1) WO2019211665A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022035A2 (pt) 2018-04-30 2021-02-02 Takeda Pharmaceutical Company Limited proteínas de ligação de receptor de canabinoide tipo 1 (cb1) e usos das mesmas
US20250326836A1 (en) 2022-06-03 2025-10-23 Shionogi & Co., Ltd. Antibody that binds to cannabinoid type 1 receptors
US20250367134A1 (en) * 2022-06-17 2025-12-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2025257151A1 (en) * 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP6562912B2 (ja) 2013-06-26 2019-08-21 アムジェン インコーポレイテッド Ｃｂ１受容体抗原結合タンパク質及びその使用
TWI694086B (zh) * 2014-03-27 2020-05-21 美商銳意公司 結合人類大麻素１（ｃｂ１）受體之抗體
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
MX2018003982A (es) * 2015-09-30 2019-01-31 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
BR112020022035A2 (pt) 2018-04-30 2021-02-02 Takeda Pharmaceutical Company Limited proteínas de ligação de receptor de canabinoide tipo 1 (cb1) e usos das mesmas

Also Published As

Publication number Publication date
US11746155B2 (en) 2023-09-05
US20210198358A1 (en) 2021-07-01
TWI882957B (zh) 2025-05-11
PE20210419A1 (es) 2021-03-08
MX2020011498A (es) 2021-01-29
EP3787746A1 (en) 2021-03-10
US20250250341A1 (en) 2025-08-07
JP2021525059A (ja) 2021-09-24
BR112020022035A2 (pt) 2021-02-02
KR20210005051A (ko) 2021-01-13
JP2024059646A (ja) 2024-05-01
TW202003549A (zh) 2020-01-16
ECSP20076576A (es) 2021-12-30
AU2019264029A1 (en) 2020-11-19
AR114436A1 (es) 2020-09-02
US12202901B2 (en) 2025-01-21
CO2020014681A2 (es) 2020-12-10
WO2019211665A1 (en) 2019-11-07
CN112218684A (zh) 2021-01-12
JP7431750B2 (ja) 2024-02-15
US20220396620A1 (en) 2022-12-15
EA202092593A1 (ru) 2021-02-12
PH12020551805A1 (en) 2021-07-26
CA3098416A1 (en) 2019-11-07
SG11202010388SA (en) 2020-11-27
MA52504A (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
CR20210176A (es) Anticuerpos estabilizadores de trem2
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
PE20250782A1 (es) Proteinas de union a antigenos trem2 y usos de estas
JOP20190247A1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
EA202191430A1 (ru) Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
MY202687A (en) Pharmaceutical chimeric receptor composition and method thereof
EP4567118A3 (en) Transgenic mammals and methods of use thereof
EA202192488A1 (ru) Антитела против tsg-6 и их применения
JOP20210300A1 (ar) أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
EA202090333A1 (ru) Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина
JOP20220074A1 (ar) أجسام مضادة لـ nrp1a واستخداماتها لعلاج العين أو أمراض العين
TH2001006259A (th) โปรตีนที่จับกับแคนนาบินอยด์รีเซพเตอร์ ไทป์ 1(cb1) และการใช้โปรตีนนั้น
CL2019001537A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.